Kilitch Drugs(I) Ltd
Thu 13/03/2025,15:41:45 | NSE : KILITCH
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 308.65
Previous Close
₹ 308.65
Volume
4682
Mkt Cap ( Rs. Cr)
₹505.95
High
₹ 319.45
Low
₹ 308.65
52 Week High
₹ 404.95
52 Week Low
₹ 300.00
Book Value Per Share
₹ 117.72
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Kilitch Drugs(I) Ltd
Your Vote -
Buy
58.33%
Hold
8.33%
Sell
33.33%
58.33%
12 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
314.60
50
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
50
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Kilitch Drugs(I) Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Kilitch Drugs(I) - Copy of Newspaper Publication
-
Kilitch Drugs(I) - Press Release
-
Kilitch Drugs(I) - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Kilitch Drugs(I) - Integrated Filing- Financial
-
Kilitch Drugs(I) - Integrated Filing (Financial)
-
Kilitch Drugs(I) Q3 net profit up 25.09% at Rs 6.88 cr
-
Kilitch Drugs(I) - Financial Result Updates
-
Kilitch Drugs(I) - Considered And Approved Unaudited Financial Result For December 31, 2024
-
Kilitch Drugs(I) - Press Release
-
Kilitch Drugs(I) - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Kilitch Drugs(I) - Board Meeting Intimation
-
Kilitch Drugs(I) - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Con
-
Kilitch Drugs(I) - Updates
-
Kilitch Drugs(I) - General Updates
-
Kilitch Drugs(I) - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulati
-
Kilitch Drugs(I) has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Kilitch Drugs(I) - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Kilitch Drugs(I) - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Kilitch Drugs(I) - Trading Window-XBRL
-
Kilitch Drugs(I) - Trading Window
Key fundamentals
Evaluate the intrinsic value of Kilitch Drugs(I) Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 254.2407 | 217.7951 | 198.366 | 177.6409 | 164.1594 |
| Liabilities | 254.2407 | 217.7951 | 198.366 | 177.6409 | 164.1594 |
| Equity | 16.0823 | 15.5823 | 15.5823 | 15.4945 | 15.4342 |
| Gross Profit | 20.3169 | 17.1734 | 10.9961 | 5.2094 | 1.3821 |
| Net Profit | 17.5738 | 15.7173 | 10.5277 | 6.1554 | 4.4571 |
| Cash From Operating Activities | -1.1932 | 6.0976 | 5.205 | 6.1254 | 7.2877 |
| NPM(%) | 13.35 | 13.34 | 10.01 | 8.79 | 7.33 |
| Revenue | 131.599 | 117.7835 | 105.1598 | 70.0168 | 60.768 |
| Expenses | 111.2821 | 100.6101 | 94.1637 | 64.8074 | 59.3859 |
| ROE(%) | 9.28 | 8.3 | 5.56 | 3.25 | 2.35 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 20 Sep 2019 | 0.5 | 5 | 0 | 172.95 |
| 18 Sep 2018 | 0.5 | 5 | 0 | 89.1 |
| 24 Sep 2012 | 30 | 300 | 0 | 69.7 |
| 18 Aug 2011 | 1 | 10 | 0 | 71.15 |
Peers
Other companies within the same industry or sector that are comparable to Kilitch Drugs(I) Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 808.20 | -1.14 | 11.41 | 179.78 | 1321.50 | 1.42 |
| Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 655.08 | 14.01 | 0.88 |
| Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 337.66 | 2.31 | 0.00 |
| Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 617.69 | -239.30 | 0.00 |
Company Info
M/s Kilitch Drugs (India) ltd was incorporated on 12th May, 1992 with the Registrar of Companies, Maharashtra at Bombay as a public limited company and obtained certificate for commencement of business dated 26-05-92. The company went Public in February 1994 for setting up a pharmaceutical formulation plant to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. The company could not commence its manufacturing activities as planned in the Public Issue on account of delay in completion of building. Till date, the company has not commenced any manufacturing activities. The land and building is now completed and in order to have the benefit of its capacity, the company is planning this rights issue for expanding its injectable capacity from 30,000 ltrs. to 75,000 Itrs. Due to delay in implementation of project, the company could not come out with its own production till date and therefore the company is presently trading in pharmaceutical formulations like tablets, capsules, liquid orals, ointments, creams and injectables. The trading turnover of the company for the year 1994-95 was Rs.550.50 Lacs. 2008 -Board recommends final dividend of 10%. 2009 -The Company got a GOLD AWARD for Quality Excellence. 2010 -Listing of Equity Shares at NSE. 2011 2015 -Kilitch Drugs entered joint venture with local firm in Ethopia 2021 -Kilitch Drugs starts production of Cephalosporins Injectables at Ethiopia Plant' dated 26th July 2021.
M/s Kilitch Drugs (India) ltd was incorporated on 12th May, 1992 with the Registrar of Companies, Maharashtra at Bombay as a public limited company and obtained certificate for commencement of business dated 26-05-92. The company went Public in February 1994 for setting up a pharmaceutical formulation plant to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. The company could not commence its manufacturing activities as planned in the Public Issue on account of delay in completion of building. Till date, the company has not commenced any manufacturing activities. The land and building is now completed and in order to have the benefit of its capacity, the company is planning this rights issue for expanding its injectable capacity from 30,000 ltrs. to 75,000 Itrs. Due to delay in implementation of project, the company could not come out with its own production till date and therefore the company is presently trading in pharmaceutical formulations like tablets, capsules, liquid orals, ointments, creams and injectables. The trading turnover of the company for the year 1994-95 was Rs.550.50 Lacs. 2008 -Board recommends final dividend of 10%. 2009 -The Company got a GOLD AWARD for Quality Excellence. 2010 -Listing of Equity Shares at NSE. 2011 2015 -Kilitch Drugs entered joint venture with local firm in Ethopia 2021 -Kilitch Drugs starts production of Cephalosporins Injectables at Ethiopia Plant' dated 26th July 2021.
Read More
Parent Organisation
Kilitch Drugs(I) Ltd.
Founded
12/05/1992
Managing Director
Mr.Mukund P Mehta
NSE Symbol
KILITCHEQ
FAQ
The current price of Kilitch Drugs(I) Ltd is ₹ 314.60.
The 52-week high for Kilitch Drugs(I) Ltd is ₹ 319.45 and the 52-week low is ₹ 308.65.
The market capitalization of Kilitch Drugs(I) Ltd is currently ₹ 505.95. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Kilitch Drugs(I) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Kilitch Drugs(I) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kilitch Drugs(I) Ltd shares.
The CEO of Kilitch Drugs(I) Ltd is Mr.Mukund P Mehta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
